The purpose of this workshop is to address challenges related to clinical trial designs and drug development in Alcoholic Associated Liver Disease (AALD) and Alcoholic Hepatitis (AH) including populations to study, endpoints, and diagnostic criteria.  For additional details visit
Alcoholic Hepatitis Workshop FDA, NIAAA, AASLD Clinical Trial Endpoints for AH
Date: March 26-27, 2018
Location: Food and Drug Administration Great Room – White Oak Campus 10903 New Hampshire Ave., Silver Spring, MD
Registration Information: 


Logistics Contact:
Bridgette Green, NIAAA



• Food and Drug Administration (FDA)
• National Institute on Alcohol Abuse and Alcoholism (NIAAA)
• American Association for the Study of Liver Diseases (AASLD)
• American College of Gastroenterology (ACG)
• American Gastroenterological Association (AGA)